Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$10.65 +2.6%	$9.36	$6.38 ▼ $17.30	$1.00B	1.42	1.23 million shs	1.64 million shs
PTGX Protagonist Therapeutics	$56.64 +2.4%	$50.79	$32.50 ▼ $60.60	$3.43B	2.26	837,199 shs	614,019 shs
SRRK Scholar Rock	$41.15 +6.2%	$33.32	$6.76 ▼ $46.98	$3.68B	0.33	1.31 million shs	2.09 million shs
VKTX Viking Therapeutics	$31.63 +3.0%	$27.81	$18.92 ▼ $81.73	$3.45B	0.62	4.05 million shs	2.63 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	+2.60%	+11.52%	+12.11%	+32.63%	-37.02%
PTGX Protagonist Therapeutics	+2.39%	+8.32%	+3.62%	+22.39%	+49.72%
SRRK Scholar Rock	+6.17%	+11.25%	+28.07%	+34.01%	+342.00%
VKTX Viking Therapeutics	+3.03%	+4.05%	+17.32%	+32.12%	-44.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	1.8231 of 5 stars	3.5	1.0	0.0	1.6	1.7	0.6
PTGX Protagonist Therapeutics	1.4574 of 5 stars	2.5	1.0	0.0	3.5	2.5	0.0
SRRK Scholar Rock	3.0841 of 5 stars	1.6	1.0	4.4	2.5	3.3	0.6
VKTX Viking Therapeutics	4.6241 of 5 stars	3.5	5.0	4.7	3.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	70.58% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	16.70% Upside
SRRK Scholar Rock	3.14	Buy	$42.67	3.69% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	175.54% Upside

Current Analyst Ratings Breakdown

Latest AVDL, SRRK, PTGX, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/18/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/3/2025	SRRK Scholar Rock	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	6.09	N/A	N/A	$0.77 per share	13.83
PTGX Protagonist Therapeutics	$434.43M	8.08	$4.62 per share	12.25	$11.33 per share	5.00
SRRK Scholar Rock	$33.19M	117.72	N/A	N/A	$3.94 per share	10.44
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	177.50	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	75.52	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.53	N/A	N/A	N/A	N/A	-118.22%	-82.01%	8/6/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest AVDL, SRRK, PTGX, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	N/A	N/A	N/A	$8.32 million	N/A
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
PTGX Protagonist Therapeutics	N/A	17.25	17.26
SRRK Scholar Rock	0.16	10.25	10.25
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
PTGX Protagonist Therapeutics	98.63%
SRRK Scholar Rock	91.08%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
PTGX Protagonist Therapeutics	4.90%
SRRK Scholar Rock	13.30%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
SRRK Scholar Rock	140	94.95 million	82.32 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

AVDL, SRRK, PTGX, and VKTX Headlines

Recent News About These Companies

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

July 16 at 4:19 PM | prnewswire.com

H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT

July 16 at 10:43 AM | insidermonkey.com

Kintayl Capital LP Grows Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 16 at 8:59 AM | marketbeat.com

Viking Therapeutics (VKTX) Projected to Post Quarterly Earnings on Wednesday

July 16 at 3:49 AM | marketbeat.com

The Best Stocks to Invest $1,000 In Right Now

July 15 at 4:40 AM | fool.com

Concurrent Investment Advisors LLC Buys New Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 13, 2025 | marketbeat.com

Principal Financial Group Inc. Sells 30,629 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 13, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Caas Capital Management LP

July 11, 2025 | marketbeat.com

Banque Pictet & Cie SA Takes Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 11, 2025 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 10, 2025 | zacks.com

U.S. Capital Wealth Advisors LLC Sells 8,423 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 10, 2025 | marketbeat.com

Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results

July 9, 2025 | insidermonkey.com

Financial Counselors Inc. Acquires 16,823 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 9, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 8.1% - Still a Buy?

July 8, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Cambridge Investment Research Advisors Inc.

July 8, 2025 | marketbeat.com

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

July 7, 2025 | fool.com

August 22nd Options Now Available For Viking Therapeutics (VKTX)

July 5, 2025 | nasdaq.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 4, 2025 | insidertrades.com

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

July 4, 2025 | fool.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 3, 2025 | zacks.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

AVDL, SRRK, PTGX, and VKTX Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$10.65 +0.27 (+2.60%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$10.64 -0.01 (-0.05%)

As of 07:14 AM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Protagonist Therapeutics NASDAQ:PTGX

$56.64 +1.32 (+2.39%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$54.27 -2.37 (-4.18%)

As of 07:00 AM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Scholar Rock NASDAQ:SRRK

$41.15 +2.39 (+6.17%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$41.01 -0.14 (-0.34%)

As of 07:19 AM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$31.63 +0.93 (+3.03%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$31.84 +0.22 (+0.68%)

As of 07:21 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time